CREBBP and lung cancer: CBP/EP300 inhibitor potentiated most the action of cisplatin (78.2-fold decline in IC50), then doxorubicin (62.7-fold), daunorubicin (53.2-fold), etoposide (28.9-fold), bleomycin (14-fold), paclitaxel (11.3-fold) and methotrexat in lung cancer cells.